

SEQUENCE LISTING

<120> MURINE EXPRESSION OF HUMAN Ig LAMBDA LOCUS

<140> PCT/GB99/03632
<141> 1999-11-03<150> GB 9823930.4
<151> 1998-11-03

<160> 23

<170> PatentIn Ver. 2.1

<210> 1
<211> 29
<212> DNA
<213> Homo sapiens<400> 1
aattctaaaa ctacaaactg cccccccca

29

<210> 2
<211> 21
<212> DNA
<213> HOMO SAPIENS<400> 2
aattctaaaa ctacaaactg c

21

<210> 3
<211> 18
<212> DNA
<213> Homo sapiens<400> 3
ctcccggtta gaagtcac

18

<210> 4
<211> 22
<212> DNA
<213> Homo sapiens<400> 4
aattcgtgtg gccttgttgg ct

22

<210> 5
<211> 234
<212> DNA
<213> HOMO SAPIENS<400> 5
gccagcatca cctgctctgg agataaaattg ggggataaaat atgcttgctg gtatcagcag 60
aaggcaggcc agtcccctgt gctggtcata tatcaagata gcaagcggcc ctcaggatc 120
cctgagcgat tctctggctc caactctggg aacacagcca ctctgaccat cagcgggacc 180
caggctatgg atgaggctga ctattactgt caggcgtggg acagcagcac tgca 234

<210> 6

<211> 231
<212> DNA
<213> Homo sapiens

<400> 6
gccaacatca cctgttctgg agataaaattt gggataaaat atgcttgctg gtatcagcag 60
aaggcaggcc agtcccstat tctgatcatc tatcaagata acaggcggcc ctcagggatc 120
cctgagcgat tctctggctc caactctggg aacacagcca ctctgaccat cagcgggacc 180
caggctatgg atgaggctga ctattattgt caggcgtggg accgcagcac t 231

<210> 7
<211> 37
<212> DNA
<213> Homo sapiens

<400> 7
ttgggtgttc ggcggaggga ccaagctgac cgcccta 37

<210> 8
<211> 36
<212> DNA
<213> Homo sapiens

<400> 8
tgggtatttcg gcggaggggac ctacctgacc gtcctg 36

<210> 9
<211> 232
<212> DNA
<213> Homo sapiens

<400> 9
gccagcatca cctgctcgag agataaaattt gggaaacat atgtttcctg gtatcggcag 60
aaggcaggcc agtcccctgt gctgctcatc tatcaagata ccaagcgacc ctcagggatc 120
cctgagcgat tctctggctc caactctggg aacacagccg ctctgaccat caccgggacc 180
caggcttgg atgaggctga ctattactgt caggcgtggg acagcgccac tg 232

<210> 10
<211> 37
<212> DNA
<213> Homo sapiens

<400> 10
tgtggtatttc ggcggaggga ccaagctgac cgcccta 37

<210> 11
<211> 35
<212> DNA
<213> Homo sapiens

<400> 11
tggttttcg gggaggggacc aaactgacca tccta 35

<210> 12
<211> 239
<212> DNA
<213> Homo sapiens

<400> 12
 gccaggatca cctgctctgg agatgcattg caaaaaaaaat atgcttattt gtaaccagcag 60
 aagtcaaggcc aggccccctgt gctgtcatc tatgaggaca gcaaacgacc ctccgggatc 120
 cctgagagat tctctggctc cagtcaggg acaatggcca ctttgactat cagtggggcc 180
 caggtggagg atgaagctga ctactactgt tactcaacag acagcagtgg taatcatag 239

<210> 13
 <211> 239
 <212> DNA
 <213> Homo sapiens

<400> 13
 gccaggatca cctgctctgg agatgcattg caaaaaaaaat atgcttattt gtaaccagcag 60
 aagtcaaggcc aggccccctgt gctgtcatc tctgaggaca gcaaacgacc ctccgggatc 120
 cctgagagaa tctctggctc cagtcaggg acaatggcca ctttgactat cagtggggcc 180
 caggtggaga atgaagctga ctactactgt tactcaacag acagcagttag tactcatag 239

<210> 14
 <211> 34
 <212> DNA
 <213> Homo sapiens

<400> 14
 ggtgttcggc ggagggacca agctgaccgt ccta 34

<210> 15
 <211> 246
 <212> DNA
 <213> Homo sapiens

<400> 15
 atcaccatct cctgcactgg aaccagcagt gacgttggtg gttataacta tgtctcctgg 60
 taccaacacg acccaggccaa agcccccaaa ctcatgattt atgaggtcag taatcgcccc 120
 tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgaccatc 180
 tctgggctcc aggctgagga cgaggctgtat tattactgca gctcatatac aagcagcagc 240
 actctc 246

<210> 16
 <211> 243
 <212> DNA
 <213> Homo sapiens

<400> 16
 atcaccatct cctgcactgg aaccagcagt gacgttggtg gttctaaactt tgtctcctgg 60
 taccaacaac acccaggccaa agcccccaaa ctcatgattt atgatgtcag ttatcgcccc 120
 tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgaccatc 180
 tctgggctcc aggctgagga cgaggctgtat tattactgctc gctcatatac aagcagcagc 240
 act 243

<210> 17
 <211> 36
 <212> DNA
 <213> Homo sapiens

<400> 17
 tgggtttcg gcggaggggac caagctgacc gtccta 36

<210> 18
<211> 239
<212> DNA
<213> Homo sapiens

<400> 18
gtcaggatca catgccaagg agacagcctc agaagctatt atgcaagctg gtaccagcac 60
aagccaggac aggcccctgt acttgtcatc tatggtaaaa acaaccggcc ctcagggatc 120
ccagaccgat tctctggctc cagctcagga aacacagctt ccttgaccat cactgggct 180
caggcgaag atgaggctga ctattactgt aactcccggg acagcagtgg taaccatct 239

<210> 19
<211> 237
<212> DNA
<213> Homo sapiens

<400> 19
gtcaggatca catgccaagg agacagcctc agaagctatt atgcaagctg gttccagcac 60
aagccaggac aggcccctgt acttgtcatc tatgctaaaa acaaccggcc ctcagggatc 120
ccagaccgat tctctggctc cagctcagga aacacagctt ccttgaccat cactgggact 180
caggcgaag atgaggctga ctattactgt aactcccggg acagcagtgg tgaacat 237

<210> 20
<211> 36
<212> DNA
<213> Homo sapiens

<400> 20
gtggtattcg gcggaggac caagctgacc gtccta 36

<210> 21
<211> 246
<212> DNA
<213> Homo sapiens

<400> 21
atcaccatct cctgcactgg aaccagcagt gatgttggga gttataacct tgcctcctgg 60
taccaacagc acccaggcaa agccccaaa ctcatgattt atgaggtagt taagcggccc 120
tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgacaatc 180
tctgggctcc aggctgagga cgaggctgat tattactgt gctcatatgc aggttagtagc 240
actttc 246

<210> 22
<211> 241
<212> DNA
<213> Homo sapiens

<400> 22
atcaccatct cctgcactgg aaccagcggt gatgttggga gttataactt tgcctcctgg 60
taccaactac acccaggcaa agtccccaaa ctcatgattt atgaagacat taagcggccc 120
tcaggggttt ctaatcgctt ttctggctcc aagtctggca acacggcctc cctgacaatc 180
tctgggctcc aggctgagga cgaggctgat tattactgt gctcatatgc aagtctgtac 240
a 241

<210> 23
<211> 38
<212> DNA

<213> Homo sapiens

<400> 23

ggtgtgtgtt cggcggaggg accaacctga ccgtccta

38

bioRxiv preprint doi: https://doi.org/10.1101/2022.05.10.488609; this version posted May 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

10. The method according to claim 7, wherein YAC-containing yeast cells are fused with HM-1 embryonic stem (ES) cells and G418 resistance colonies are picked and analysed 2-3 weeks after protoplast fusion.
11. The method according to claim 7, wherein ES cells containing a complete HuIg λ YAC copy are used for blastocyte injection to produce a chimeric animal.
12. The method according to claim 11, wherein breeding of a chimeric animal with a Balb/c mouse results in germline transmission.
13. The method according to claim 12, comprising breeding the mouse with $\kappa^{-/-}$ mice to establish lines of transgenic mice.
14. A hybridoma obtainable from a three month old HuIg λ YAC/ $\kappa^{+/-}$ mouse by fusion of splenocytes with NSO myeloma cells, and subsequent selection of single clones.
15. Antibodies obtained from a hybridoma according to claim 14.

16. A transgenic mouse comprising as a translocus a yeast artificial chromosome (YAC) of greater than 100Kb which contains a proportion of the human V λ genes proximal to the J λ -C λ cluster in germline configuration.
17. The transgenic mouse according to claim 16, wherein the YAC includes a 380 Kb region of the human Ig λ locus in authentic configuration with most V λ genes of cluster A, J λ -C λ segments and the 3' enhancer.
18. A transgenic mouse comprising variable, joining and constant genes of the human λ light chain locus as a transgenic locus on a YAC, wherein B cells of said mice rearrange said λ light chain genes and the mice express serum immunoglobulins containing human λ light chains.
19. The transgenic mouse comprising human λ light chain genes according to claim 16, wherein the λ translocus is rearranged with similar efficiency as endogenous mouse κ and at the same time as or before the endogenous κ locus.
20. The transgenic mouse comprising human λ light chain genes according to claim 16, wherein the endogenous κ locus has been silenced, and the mouse expresses serum immunoglobulins containing human λ light chains.

21. The transgenic mouse carrying human λ light chain genes according to claim 16, further comprising human heavy chain genes as a second transgenic locus integrated on a separate YAC, wherein the mouse expresses serum immunoglobulin molecules containing combinations of human heavy and λ light chains.
22. The transgenic mouse carrying human λ light chain genes according to claim 21, wherein the second transgenic locus carries a diversity of human heavy chain constant region genes, including μ , δ and γ genes.
23. The transgenic mouse carrying human λ light chain genes and human heavy chain genes according to claim 22, wherein the heavy chain transgenic locus carries a diversity of human heavy chain constant region genes, including μ , δ and γ genes, in authentic germline configuration.
24. The transgenic mouse carrying human λ light chain genes according to claim 16, further comprising human κ light chain genes as a second transgenic light chain locus integrated on a separate YAC, wherein the mouse expresses serum immunoglobulin molecules containing human κ and λ light chains.
25. The transgenic mouse carrying human λ light chain genes according to claim 16, further comprising human heavy chain genes as a second transgenic locus and human κ light chain genes as a third transgenic locus, wherein the mouse

expresses serum immunoglobulin molecules containing human heavy chains in combination with human κ or λ light chains.

26. The transgenic mouse carrying human λ light chain genes according to claim 16, wherein expression of the endogenous mouse heavy and/or light chain loci has been prevented through gene targeting or other means and which expresses serum immunoglobulin containing human heavy and/or light chains and which are deficient in production of mouse immunoglobulin.
27. A transgenic mouse carrying human λ light chain genes in which expression of the human λ locus is equal to or greater than that of the endogenous or transgenic human κ locus.
28. The transgenic mouse carrying human λ light chain genes according to claim 27, wherein the λ translocus has been bred to homozygosity.
29. The transgenic mouse carrying human λ light chain genes according to claim 27, wherein the rearranged variable genes in the λ translocus are subject to somatic hypermutation.
30. A method for production of human antibodies comprising stimulating with antigen transgenic mice incorporating human λ light chain genes into their genome and collecting the human antibodies which bind to the antigen.

31. A method for production of human monoclonal antibodies from transgenic mice and immunised as in claim 30, by creation of hybridomas through fusion to an appropriate mouse myeloma cell line.
32. Human monoclonal antibodies comprising human heavy and light chains of diverse isotypes and chain combinations produced from transgenic mice carrying the human λ translocus.
33. Human monoclonal antibodies according to claim 32, wherein the variable regions of the human λ light chains have undergone somatic mutation.
34. Human monoclonal antibodies according to claim 32, wherein the antibodies have an affinity for antigen of greater than 10^{-8} M.